← Back to Screener
PAVmed Inc. Common Stock (PAVM)
Price$9.11
Favorite Metrics
Price vs S&P 500 (26W)-38.51%
Price vs S&P 500 (4W)-16.54%
Market Capitalization$58.15M
P/E Ratio (Annual)145.01x
All Metrics
Book Value / Share (Quarterly)$36.61
P/TBV (Annual)3.63x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-42.83%
Cash Flow / Share (Quarterly)$-5.64
Price vs S&P 500 (YTD)38.29%
Gross Margin (TTM)-205.63%
Net Profit Margin (TTM)564.79%
EPS (TTM)$-17.84
10-Day Avg Trading Volume0.01M
EPS Excl Extra (TTM)$-17.84
EPS (Annual)$0.60
ROI (Annual)0.89%
Gross Margin (Annual)-207.04%
Net Profit Margin (5Y Avg)-6841.93%
Cash / Share (Quarterly)$2.10
P/E Basic Excl Extra (TTM)145.01x
Revenue Growth QoQ (YoY)420.00%
P/E Normalized (Annual)145.01x
ROA (Last FY)1.03%
Revenue Growth TTM (YoY)-97.63%
EBITD / Share (TTM)$-11.06
ROE (5Y Avg)-440.28%
Operating Margin (TTM)-30797.18%
Cash Flow / Share (Annual)$-5.64
P/B Ratio1.71x
P/B Ratio (Quarterly)0.19x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)947.86x
Net Interest Coverage (TTM)-166.22x
ROA (TTM)0.92%
EV / EBITDA (TTM)1.17x
EPS Incl Extra (Annual)$0.60
Current Ratio (Annual)0.17x
Quick Ratio (Quarterly)0.15x
3-Month Avg Trading Volume0.70M
52-Week Price Return-56.83%
P/E Incl Extra (TTM)145.01x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.05
P/S Ratio (Annual)819.01x
Asset Turnover (Annual)0.00x
52-Week High$28.44
Operating Margin (5Y Avg)-13979.48%
EPS Excl Extra (Annual)$0.60
CapEx CAGR (5Y)-12.37%
26-Week Price Return-34.53%
Quick Ratio (Annual)0.15x
13-Week Price Return14.76%
Total Debt / Equity (Annual)0.33x
Current Ratio (Quarterly)0.17x
Enterprise Value$67.298
Asset Turnover (TTM)0.00x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-3477.46%
Cash / Share (Annual)$2.10
3-Month Return Std Dev212.14%
Gross Margin (5Y Avg)-260.22%
Net Income / Employee (TTM)$0
ROE (Last FY)1.18%
Net Interest Coverage (Annual)-0.22x
EPS Basic Excl Extra (Annual)$0.60
Receivables Turnover (TTM)4.30x
Total Debt / Equity (Quarterly)0.33x
EPS Incl Extra (TTM)$-17.84
Receivables Turnover (Annual)4.30x
ROI (TTM)0.85%
P/S Ratio (TTM)819.01x
Pretax Margin (5Y Avg)-8831.06%
Revenue / Share (Annual)$0.11
Tangible BV / Share (Annual)$0.69
Price vs S&P 500 (52W)-86.66%
P/E Ratio (TTM)145.01x
Year-to-Date Return40.94%
5-Day Price Return-4.26%
EPS Normalized (Annual)$0.60
ROA (5Y Avg)-57.14%
Net Profit Margin (Annual)564.79%
Month-to-Date Return-8.08%
Cash Flow / Share (TTM)$-0.82
EBITD / Share (Annual)$-16.19
Operating Margin (Annual)-30794.37%
ROI (5Y Avg)-120.16%
P/E Excl Extra (TTM)145.01x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-17.84
P/TBV (Quarterly)15.65x
P/B Ratio (Annual)0.19x
Inventory Turnover (TTM)34.81x
Pretax Margin (TTM)-3477.46%
Book Value / Share (Annual)$36.61
Price vs S&P 500 (13W)14.07%
Beta0.79x
Revenue / Share (TTM)$0.08
ROE (TTM)1.02%
52-Week Low$6.00
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.13
4.13
4.13
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
PAVMPAVmed Inc. Common Stock | 819.01x | — | -205.63% | -30797.18% | $9.11 |
SYKStryker Corporation | 5.15x | 11.84% | 64.57% | 19.43% | $338.38 |
BSXBoston Scientific Corp. | 4.76x | 15.16% | 69.01% | 18.00% | $63.42 |
MMM3M Company | 3.18x | -4.97% | 39.92% | 18.55% | $150.55 |
MDLNMedline Inc. Class A common stock | 2.21x | — | 26.44% | 7.78% | $46.94 |
BDXBecton, Dickinson and Co. | 2.01x | 6.32% | 46.42% | 12.15% | $154.82 |
RMDResMed Inc. | 6.06x | 11.72% | 60.85% | 33.70% | $224.72 |
DXCMDexCom, Inc. | 5.23x | 19.33% | 62.09% | 19.56% | $61.23 |
WSTWest Pharmaceutical Services, Inc. | 6.22x | 7.44% | 35.91% | 19.03% | $269.81 |
PODDInsulet Corporation | 5.31x | 24.53% | 71.63% | 12.92% | $201.47 |
PENPenumbra, Inc. | 9.31x | 20.16% | 67.14% | 13.48% | $331.47 |
About
PAVmed Inc is a commercial-stage medical technology company developing products across diagnostics, medical devices, and digital health. Its portfolio includes EsoGuard, esocheck, and the Veris Cancer Care Platform. The company is advancing its pipeline through commercialization to serve multiple healthcare markets.